Jeffrey Carlisle, MD
Ophthalmology · Lilburn, GANPI 1992702450
Payments from drug & device makers
Across 171 payments — averaging $47.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Carl Zeiss Meditec USA, Inc.$1K
- Glaukos Corporation$829
- Alcon$779
- Coopervision Inc.$500
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,66482%
- Education$5186%
- Other$93011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,636 |
| Johnson & Johnson Surgical Vision, Inc. | 39 | $1,581 |
| Carl Zeiss Meditec USA, Inc. | 2 | $1,099 |
| Glaukos Corporation | 11 | $829 |
| Alcon | 16 | $779 |
| Coopervision Inc. | 2 | $500 |
| Carl Zeiss Meditec, Inc. | 3 | $284 |
| NEW World Medical,inc. | 2 | $220 |
| Bausch & Lomb Americas Inc. | 5 | $188 |
| Rxsight Inc | 2 | $173 |
| Biotissue Holdings Inc. | 3 | $155 |
| Alimera Sciences, Inc. | 1 | $127 |
| Sun Pharmaceutical Industries Inc. | 2 | $127 |
| Novartis | 7 | $126 |
| Apellis Pharmaceuticals, Inc. | 1 | $103 |
| Dompe US, Inc. | 2 | $47 |
| Oyster Point Pharma, Inc. | 1 | $30 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| Harrow Eye, LLC | 1 | $23 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMERA 700$1,099
- Tecnis IOL$769
- MiSight Contact Lens$500
- iStent Trabecular Micro-Bypass System Model iS3$160
- Clareon$149
- RXSIGHT CONTACT LENS$144
- RXSIGHT INJECTOR CARTRIDGE$144
- RXSIGHT INJECTOR HANDPIECE$144
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$144
- LIGHT ADJUSTABLE LENS (LAL)$144
- Clareon PanOptix Pro$139
- NGENUITY$137
- iDoseTR$135
- OPMI Lumera$134
- Iluvien$127
- DURYSTA$125
- LUMIGAN$125
- COMBIGAN$125
- Kahook Dual Blade$119
- Clearpath$119
How this compares
$8,112 in reported general payments places this provider in the 75th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 178 | $88,400 |
| RestasisCyclosporine | 53 | $49,664 |
| XiidraLifitegrast | 19 | $21,646 |
| VyzultaLatanoprostene Bunod | 38 | $18,304 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $12,128 |
| Travoprost | 71 | $9,623 |
| Cyclosporine | 17 | $9,093 |
| Loteprednol Etabonate | 42 | $8,001 |
| Carteolol Hcl | 175 | $5,239 |
| Alphagan PBrimonidine Tartrate | 14 | $4,574 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 309 | $3,220 |
| Latanoprost | 261 | $2,167 |
| Ketorolac Tromethamine | 47 | $1,006 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 74 | $798 |
| Prednisolone Acetate | 23 | $678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,636 | $154,765270 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $188 | $39,95057 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Lilburn
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.